NovoCure's TTFields shows survival breakthrough in pancreatic cancer trial

NovoCure Ltd. has announced promising results from its PANOVA-3 study, testing Tumor Treating Fields (TTFields) in patients with locally advanced pancreatic cancer. The interim findings show a clear survival advantage, pushing the company's stock up by 15% on NASDAQ in a single day. Analysts now see broader potential for the technology beyond its original use in glioblastoma.

The PANOVA-3 trial compared patients receiving TTFields alongside standard care to those on standard treatment alone. Those using the device achieved a median progression-free survival of 12.5 months, compared to just 8.7 months in the control group. These interim results have prompted NovoCure to plan regulatory submissions, with an FDA application expected in late 2026 and an EMA filing to follow.

TTFields, already approved for glioblastoma, delivers low-intensity electric fields to disrupt cancer cell division. Its success in pancreatic cancer could open doors for other solid tumours, expanding NovoCure's market reach. Leading European centres, including Charité Berlin, have begun testing the system, reflecting strong clinical interest—particularly in Germany. Financially, NovoCure reported $150 million in revenue last quarter and holds $400 million in cash reserves. This funding is projected to cover operations for the next 24 months. The positive trial data has also led firms like Leerink and BTIG to raise their price targets for the company's stock.

The PANOVA-3 results position TTFields as a potential breakthrough for pancreatic cancer treatment. NovoCure's planned regulatory filings in 2026 will determine its path to wider adoption in the US and Europe. With strong financial backing and growing clinical support, the technology's expansion into new cancer types appears increasingly likely.